A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure

BACKGROUND: Pathological cardiac hypertrophy is commonly resulted from sustained pressure overload and/or metabolic disorder and eventually leads to heart failure, lacking specific drugs in clinic. Here, we aimed to identify promising anti-hypertrophic drug(s) for heart failure and related metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhenya, Shi, Wei, Wu, Taibo, Peng, Tian, Wang, Xiaoming, Liu, Shuaiyang, Yang, Zifeng, Wang, Jia, Li, Peng-Long, Tian, Ruifeng, Hong, Ying, Yang, Hailong, Bai, Lan, Hu, Yufeng, Cheng, Xu, Li, Hongliang, Zhang, Xiao-Jing, She, Zhi-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043402/
https://www.ncbi.nlm.nih.gov/pubmed/36998980
http://dx.doi.org/10.3389/fcvm.2023.1130635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043402/
https://www.ncbi.nlm.nih.gov/pubmed/36998980
http://dx.doi.org/10.3389/fcvm.2023.1130635

Ejemplares similares